Tradjenta (Linagliptin)

Linagliptin is a medicine used to help control blood sugar levels in people with type 2 diabetes. It works by making the body use insulin better and reducing sugar production. It's taken as a pill, usually once a day.

Brand names:Tradjenta, Trajenta
Medication

What people taking Tradjenta (Linagliptin) report

Every report comes from a Lived member, sent anonymously.

Have you tried Tradjenta (Linagliptin) for Type 2 Diabetes?

NameHow it went

About Tradjenta (Linagliptin)

What It's For

Linagliptin, sold under the brand name Tradjenta, is a prescription tablet that lowers blood sugar in adults with type 2 diabetes. It is meant to work alongside healthy eating and physical activity, not replace them. It belongs to a group of diabetes medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) and has been studied both on its own and added to other diabetes treatments, including metformin, sulfonylureas, pioglitazone and insulin. Linagliptin is also one ingredient in several combination tablets: Jentadueto (linagliptin with metformin), Glyxambi (linagliptin with empagliflozin, a different type of diabetes medicine called an SGLT2, or sodium-glucose co-transporter 2, inhibitor) and Trijardy XR (all three). Those products carry the other ingredients' own instructions and warnings, so this page focuses on linagliptin itself. Linagliptin does not work for type 1 diabetes, in which the body makes little or no insulin of its own. It is not known whether people who have had pancreatitis (inflammation of the pancreas) before are at higher risk with it.

How It Works

When you eat, your gut releases hormones called incretins, mainly GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These hormones prompt the pancreas to release insulin, which moves sugar out of the blood and into cells. GLP-1 also reduces glucagon, a hormone that tells the liver to release stored sugar. An enzyme called DPP-4 normally breaks the incretin hormones down. Linagliptin blocks DPP-4, so more of the body's own incretin hormones stay active. The extra insulin is released mainly when blood sugar is normal or raised, and less sugar comes out of the liver. The result is lower blood sugar after meals and between them. In clinical trials, body weight did not change compared with a placebo.

Dosage & Administration

Tradjenta is a 5-milligram (mg) tablet taken once a day, with or without food. The same dose is used for people with reduced kidney function, including severe kidney disease, so kidney test results do not change how it is taken. If a dose is missed, take it when you remember. If it is almost time for the next dose, skip the missed one; do not take two doses to make up for it. The combination tablets that contain linagliptin come in different strengths and schedules, so follow the instructions for the exact product prescribed.

Side Effects

In clinical trials, the most common side effect was a stuffy or runny nose and sore throat (nasopharyngitis), reported by about 7% of people taking linagliptin compared with about 6% taking a placebo. Diarrhea and cough were also slightly more common than with placebo. A few less common reactions need attention: Pancreatitis is rare but can be serious. Persistent, severe belly (abdominal) pain, sometimes spreading to the back and with or without vomiting, is the main warning sign. Stop linagliptin and contact the prescriber right away if it happens. Serious allergic reactions have occurred, mostly within the first three months and sometimes after the first dose. Swelling of the face, lips, tongue or throat, or trouble breathing or swallowing, is an emergency: stop the medicine and call 911. Anyone who has had an allergic reaction to linagliptin should not take it again. A new rash, hives, or flaking or peeling skin should be reported to the prescriber promptly. Bullous pemphigoid, a skin condition that causes blisters, has been reported and sometimes needed hospital care. Severe, disabling joint pain has also been reported; it can begin anywhere from a day to years after starting and usually eases once the medicine is stopped. Tell the prescriber about new blisters, raw patches of skin, or severe joint pain.

Interactions & Warnings

Linagliptin raises the risk of low blood sugar (hypoglycemia) when it is combined with insulin or with a sulfonylurea such as glimepiride, a tablet that pushes the pancreas to release more insulin. When linagliptin is added, the prescriber may lower the dose of those medicines. Low blood sugar can cause shaking, sweating, nervousness, irritability or confusion, dizziness and hunger; many people with diabetes treat a reading below 70 mg/dL, though the threshold can differ from person to person. Rifampin, an antibiotic used mainly for tuberculosis, lowers linagliptin levels in the body and can make it less effective. Other medicines that lower its levels in the same way have a similar effect, including the seizure medicines carbamazepine and phenytoin and the herbal supplement St. John's wort, so a different diabetes treatment is strongly recommended for anyone who needs one of them. Tell the prescriber and pharmacist about every medicine and supplement you take, including those bought without a prescription. Two other medicines in the DPP-4 group were linked to heart failure in large trials. Before starting linagliptin, the prescriber weighs this for people with a history of heart failure or kidney problems. Increasing shortness of breath, rapid weight gain or swelling of the feet should be reported to the care team as soon as possible. Anyone who has had angioedema (deep swelling of the face, lips or throat) with another DPP-4 inhibitor should tell the prescriber, because it is not known whether linagliptin carries the same risk for them. There is too little information on linagliptin in pregnancy to judge its risk, while poorly controlled diabetes itself carries real risks for both parent and baby. It is not known whether linagliptin passes into breast milk. Anyone pregnant, planning pregnancy or breastfeeding should review the diabetes plan with their care team.

What to Expect

Progress is measured mainly by the A1C test, a blood test that reflects average blood sugar over about the past three months and is reported as a percentage. For many adults with diabetes the goal is below 7%, though individual targets differ. In trials where people with an A1C between 7% and 10% took linagliptin alone for 18 to 24 weeks, A1C fell by about 0.4 percentage points from a starting average near 8%, while it rose slightly with placebo. The gap between the groups was about 0.6 to 0.7 points, and people who start higher tend to see larger drops. If A1C stays above target, the prescriber may add or change medicines. Linagliptin lowers blood sugar but has not been shown to protect the heart. In a large trial of adults with type 2 diabetes and heart or kidney disease, it neither raised nor lowered the risk of heart attack, stroke or death from heart disease compared with placebo over about two years. A second large trial found heart outcomes similar to glimepiride. Linagliptin helps control high blood sugar but does not cure diabetes, so it is usually continued long term. Keep taking it even when you feel well, and talk to the prescriber before stopping. Regular A1C checks, at least twice a year for many people, show whether it is still doing enough.

Questions to Ask Your Doctor

  1. 1.Why is linagliptin a good fit for me compared with other diabetes medicines, especially ones that also protect the heart or kidneys?
  2. 2.How much should my A1C come down, and when will we check whether it is working?
  3. 3.Should the dose of my insulin or sulfonylurea change, and what blood sugar reading should prompt me to call?
  4. 4.Does my heart or kidney history change whether linagliptin is safe for me?
  5. 5.If I take a combination tablet, which warnings come from the other ingredients?

Last reviewed • Oct 2026

Educational content, not medical advice.